The dismal outcome of pleuropericardial extramedullary multiple myeloma (EMM) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib-resistant patients, as may provide much longer overall survival than previously reported treatments.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538069 | PMC |
| http://dx.doi.org/10.1002/ccr3.1015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation.
Transplant Cell Ther
December 2024
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:
Background: Patients with multiple myeloma without high-risk cytogenetic abnormalities are classified as having standard-risk MM (SRMM), and data focusing on their outcomes after autologous stem-cell transplantation (autoHCT) are limited.
Objective: To evaluate survival outcomes for patients with SRMM receiving autoHCT, and to elucidate factors that impact these outcomes.
Study Design: Single-center retrospective analysis that included consecutive MM patients who received upfront autoHCT between 2013-2021, had available cytogenetic information and had no high-risk chromosomal abnormalities on fluorescence in situ hybridization (FISH), defined as t(4;14), t(14;16), del(17p) or 1q21 gain or amplification.
Advancements in the Treatment of Multiple Myeloma.
Cureus
December 2024
Hematology, Hospital Clínica Bíblica, San José, CRI.
Multiple myeloma (MM) is the second most common hematological malignancy globally. Despite its reputation as an aggressive and fatal disease, recent advancements in treatment have significantly improved patient outcomes. Over the past decade, innovative therapies with fewer side effects have emerged, including proteasome inhibitors (e.
View Article and Find Full Text PDFTreatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study.
Leuk Lymphoma
December 2024
iOMEDICO, Freiburg im Breisgau, Germany.
Therapy adherence can significantly influence the outcome of cancer patients. The prospective, non-interventional CARO study (NCT02970747) investigated adherence, effectiveness, and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) in the German real-world setting. In total, 359 patients were included at 69 sites.
View Article and Find Full Text PDFHealth-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study.
Eur J Haematol
December 2024
Quality of Life Research Center, Department of Haematology, Odense University Hospital, Odense, Denmark.
Background: In the CONPET study, multiple myeloma patients with abnormal 18FDG positron emission/computed tomography scan after upfront autologous stem cell transplantation were treated with four cycles of carfilzomib-lenalidomide-dexamethasone (KRd). Side effect registrations show that carfilzomib might cause dyspnea, cough, respiratory tract infections, and heart failure. The aims were to investigate patient-reported shortness of breath and dyspnea during KRd consolidation.
View Article and Find Full Text PDFSurvival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison.
Future Oncol
November 2024
Bristol Myers Squibb, Princeton, NJ, USA.
Aims: Limited head-to-head data exist for daratumumab plus pomalidomide and dexamethasone (DPd) and non-pomalidomide-containing triplet regimens to treat relapsed/refractory multiple myeloma (RRMM). This study conducted population-adjusted indirect comparisons of overall survival (OS) for DPd vs. daratumumab, carfilzomib, and dexamethasone (DKd) and daratumumab, bortezomib, and dexamethasone (DVd).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!